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Abstract
Introduction: Increasing evidence indicates that features suggestive of neuropathic pain may also be present in
patients with common rheumatic conditions. The objective of this study was to examine neuropathic-like pain
symptoms and associated factors in patients with rheumatoid arthritis.
Methods: We used the painDETECT screening tool to identify possible or likely neuropathic pain in 159 outpatients
with rheumatoid arthritis. Patients additionally completed other self-reported measures, while clinical measures were
assessed to calculate the 28-joint Disease Activity Score. Univariate analyses and multivariable logistic regression were
used to identify factors associated with neuropathic pain features.
Results: According to the painDETECT, 27 patients (17.0 %) were classified as having likely neuropathic pain and 34
patients (21.4 %) as having possible neuropathic pain. Besides reporting more severe pain, patients with likely or possible
neuropathic pain were more likely to meet the diagnostic criteria for fibromyalgia, to use analgesics, and to have more
tender joints and a worse physical and mental health status as measured by the 36-item Short-Form health survey. In
multivariable analysis, physical (P < 0.001) and mental health status (P = 0.006) remained significantly associated with
neuropathic pain features, even after controlling for pain severity.
Conclusions: These findings suggest that a sizeable proportion of patients with relatively well-controlled rheumatoid
arthritis report symptoms suggestive of neuropathic pain. Neuropathic-like pain symptoms are independently associated
with worse self-reported physical and mental health.
Introduction
Rheumatoid arthritis (RA) is the most common type of
autoimmune arthritis. For patients with RA, pain is the
predominant impairment and most important priority
for improvement [1]. RA pain is traditionally attributed
to peripheral inflammation of the joints [2]. In recent
years much progress has been made in the treatment of
RA and especially in reducing this inflammation. With
the help of combinations of disease-modifying antirheu-
matic drugs (DMARDs) and biologic therapies, an in-
creasing number of RA patients now experience
extensive periods of low disease activity. Some patients
even reach sustained remission. However, pain control is
often inadequate and significant pain persists in a
substantial proportion of patients, even when inflamma-
tion appears to be well controlled [3].
This suggests that inflammation or subsequent joint
damage might not be the only factor causing pain in RA.
Although pain in RA is often described as ‘gnawing’ or
‘aching’, descriptors that have typically been associated
with nociceptive pain, some RA patients also use typical
neuropathic pain (NP) qualities such as ‘burning’ or
‘prickling’ [4–6]. NP is assumed to be caused by a lesion
or disease affecting the somatosensory nervous system
[7]. It is maladaptive and persists in the absence of nox-
ious stimuli and no, or minimal, peripheral inflammatory
pathology [8]. NP symptoms include several abnormal
sensations, including hyperalgesia and allodynia.
Although there is generally no apparent lesion of the ner-
vous system, accumulating evidence suggests that symp-
toms of NP may also be present in patients with rheumatic
conditions such as fibromyalgia (FM) or osteoarthritis.
Prevalence estimates of NP-like features have ranged from
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around 30 % in osteoarthritis [9–11] to 50–75 % in FM
[12, 13]. Recently, Wu et al. [14] also demonstrated a NP
component in ankylosing spondylitis, a disease regarded
as prototypical of inflammatory pain. A mixed pain con-
cept, in which different pain mechanisms operate, may
also be applicable to RA. As NP does not respond consist-
ently to traditional anti-inflammatory RA medications
[15], and may be associated with detrimental quality of life
[10, 16, 17], it is important to explore the presence of NP
symptoms in RA.
Screening tools based on verbal pain descriptors and
pain qualities are frequently used to distinguish NP from
other types of chronic pain [18]. One of these measures
is the painDETECT [19], a self-report questionnaire with
nine items that does not require a clinical examination.
To date, few studies have specifically examined the preva-
lence of NP features in RA. Only three studies in (subsam-
ples of) RA patients estimated the prevalence of NP using
screening tools such as the painDETECT [20–22]. How-
ever, prevalence rates of likely NP varied widely between
5 % and 36 %. Moreover, in addition to the small sample
sizes involved, none of these studies investigated multivar-
iable associations with sociodemographic and clinical fac-
tors. Therefore, the objectives of this study were to
examine the occurrence of neuropathic-like pain symp-
toms in patients with RA using the painDETECT ques-
tionnaire and to investigate possible associated factors.
Methods
Study population and data collection
Data for this study were collected within the Dutch
Rheumatoid Arthritis Monitoring (DREAM) registry. The
DREAM registry is a prospective, multicenter initiative to
monitor the course of RA patients in the Netherlands.
Both patient-reported and clinical outcomes are collected
and monitored using a web-based data acquisition and
storage system. Patient-reported outcomes are generally
completed preceding each visit to the outpatient clinic.
Between June 2013 and April 2014, RA patients from the
Medisch Spectrum Twente hospital participating in the
DREAM registry were informed about the study and in-
vited to participate upon logging on to their patient portal.
According to the Dutch Medical Research Involving
Human Subjects Act, the study did not need approval of
the ethical review board as only (nonintervention) studies
with a high burden for patients have to be reviewed. All
DREAM patients have provided written informed consent
to participate in the registry. Patients were fully informed
about the nature of this additional survey study and the
voluntary nature was emphasized.
Measures
Patients completed a series of standardized questionnaires.
Additional information was gathered on sociodemographics,
disease duration, self-reported pain medication, and smok-
ing and alcohol use.
The painDETECT
NP symptoms were assessed using the Dutch version of
the painDETECT [23]. The painDETECT consists of
seven items evaluating pain qualities, one evaluating the
course pattern of pain, and one evaluating pain radiation.
Additionally, the questionnaire contains three 0–10 nu-
merical rating scales (NRSs) for current, worst, and aver-
age pain severity. An overall score is generated that
summarizes everything but the pain intensity NRSs, which
ranges between −1 and 38. An overall score >18 indicates
likely NP, 13–18 possible NP, and <13 unlikely NP [19].
The Fibromyalgia Survey Questionnaire
The Fibromyalgia Survey Questionnaire (FSQ) was used
to assess whether the RA patients met the modified
ACR 2010 diagnostic criteria for FM [24]. The FSQ con-
sists of the widespread pain index (WPI) of 19 areas of
the body and a symptom severity score (SSS) addressing
fatigue, waking unrefreshed, and cognitive symptoms to-
gether with further somatic symptoms. Patients satisfy
the FM survey criteria if WPI ≥7 and SSS ≥5 or when
WPI between 3–6 and SSS ≥9.
The Health Assessment Questionnaire disability index
Physical disability was assessed with the Health Assess-
ment Questionnaire disability index (HAQ-DI) which
contains 20 items measuring physical disabilities over
the past week in eight categories of daily living [25].
Items are scored from 0 (without any difficulty) to 3 (un-
able to do). A total score is calculated by averaging the
highest score in each category (corrected for the use of
aids and devices) if at least six categories are completed.
The SF-36v2 health survey
Health status was measured using the 36-item Short-
Form (SF-36) Health Survey version 2 (SF-36v2) which as-
sesses eight different aspects of health [26]. Item scores
can be aggregated into a physical component summary
(PCS) and mental component summary (MCS) score. The
component summary scores are standardized using nor-
mative data from the 1998 US general population with a
mean score of 50 and a standard deviation (SD) of 10.
Clinical assessment of disease activity
Clinical data were collected during the patient’s visit to
the outpatient clinic, including a 28-tender joint count
(TJC), 28-swollen joint count (SJC), the erythrocyte sedi-
mentation rate (ESR) and C-reactive protein (CRP). The
TJC and SJC examinations were conducted by a trained
rheumatology nurse. The TJC, SJC, and ESR were used to
compute the CRP, C-reactive protein (DAS28). DAS28
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scores range between 0 and 10, with a score <2.6 indicat-
ing clinical remission and ≤3.2 representing low disease
activity [27].
Statistical analyses
Patients with possible or likely NP symptoms (painDE-
TECT ≥13) were compared to patients without NP symp-
toms. Univariate differences were examined using
independent t-tests for normally distributed variables,
Mann–Whitney U tests for non-normally distributed vari-
ables, and chi-square tests (with Yates’ continuity correc-
tion as appropriate) for categorical variables. Variables with
a marginal significance (P ≤ 0.20) in the univariate analyses
were included in a multivariable binary logistic regression
model to identify unique associations with NP symptoms.
To avoid multicollinearity problems, Pearson correlations
were calculated between the independent variables. In case
of highly related variables (r > 0.5), only one variable was
considered for the initial logistic regression model. Final
models were additionally controlled for current, worst, and
average pain severity. Multivariable models were tested for
goodness of fit with the Hosmer and Lemeshow test. The
explained variance was examined using Nagelkerke’s
pseudo R2. Statistical significance was defined as P ≤ 0.05
(two-tailed). All analyses were performed with SPSS 22
(SPSS Inc., Chicago, IL).
Results
Patient characteristics
In total, 174 patients completed the painDETECT before
their visit to the outpatient clinic. Complete medical and
clinical data were available for 159 patients. Most pa-
tients had well-controlled disease activity (Table 1).
Of the 159 patients, 119 (74.8 %) were in remission
(DAS28 < 2.6) and another 21 (13.2 %) had low disease ac-
tivity (DAS28 2.6–3.2). The majority of patients were being
treated with a DMARD (or DMARD plus prednisolone)
and/or a biologic agent at the time of the study. A total
of 101 patients (63.5 %) were prescribed nonsteroidal
anti-inflammatory drugs (NSAIDs) continuously or on-
demand, while only 4 (2.5 %) were prescribed non-
NSAID analgesics.
Neuropathic pain features
Despite relatively low disease activity, 70 patients (44 %)
reported clinically significant pain in the past 4 weeks
(average pain score ≥4 on the 10-point NRS) on the
painDETECT (Table 2). According to the painDETECT
scores, 17.0 % (exact 95 % confidence interval (CI)
11.5–23.7) of the patients had likely NP and 21.4 %
(exact 95 % CI 15.3–28.6) had possible NP features. Most
common pain qualities mentioned were pain attacks like
electric shocks (34.6 %) and pain with slight pressure
(45.3 %), but other clinically relevant somatosensory
symptoms such as burning and prickling pain were also
reported by approximately 25 % of patients. More than
one-third of patients experienced radiating pain. Total
painDETECT scores correlated moderately with pain se-
verity, ranging from r = 0.51 for current pain to r = 0.56
for strongest pain (P < 0.001 for both).
Bivariate associations with neuropathic pain features
Patients with possible or likely NP symptoms did not
significantly differ from those with no NP symptoms on
any of the measured sociodemographic characteristics
(Table 3). Prescribed DMARD and biologic therapy was
almost identical for both groups. Although the propor-
tion of patients that were prescribed continuous or on-
demand NSAIDs was also very similar in the non-NP and
Table 1 Patient characteristics (n = 159)
Female sex, n (%) 104 (65.4)





Current smoking (yes), n (%) 27 (17.0)
Current alcohol use (yes), n (%) 120 (75.5)
Disease duration (years), median (IQR) 6.0 (3.0–12.0)
Concomitant FM (yes), n (%) 23/158 (14.6)
Prescribed RA medication
DMARD 95 (59.7)
DMARD plus biologic 40 (25.2)
Biologic only 18 (11.3)
NSAID only 5 (3.1)
Other painkiller only 1 (0.6)
Self-reported current pain
medication (yes), n (%)
81/158 (51.3)
Self-reported current neuropathic
pain medication (yes), n (%)
9/158 (5.7)
DAS28 (0–10), mean ± SD 2.1 ± 1.0
ESR (mm/hour), median (IQR) 8.0 (5.0–17.0)
CRP (mg/l), median (IQR) 3.0 (1.0–7.0)
SJC (0–28), median (IQR) 0 (0–1)
TJC (0–28), median (IQR) 0 (0–1)
HAQ-DI (0–3), mean ± SD 0.7 ± 0.6
SF-36 PCS (0–100), mean ± SD 41.7 ± 9.4
SF-36 MCS (0–100), mean ± SD 50.3 ± 10.3
CRP C-reactive protein, DAS28 28-joint Disease Activity Score, DMARD
disease-modifying antirheumatic drug, ESR erythrocyte sedimentation rate,
FM fibromyalgia, HAQ-DI Health Assessment Questionnaire disability index
(standard scoring), IQR interquartile range, MCS mental component summary,
NSAID nonsteroidal anti-inflammatory drug, PCS physical component summary,
RA rheumatoid arthritis, SF-36 36-item Short-Form health survey, SJC swollen joint
count, TJC tender joint count
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NP group (62.2 % versus 65.6 %, respectively; P = 0.67),
NP patients were almost twice as likely to report actual
current use of paracetamol and NSAIDs. Additionally, sig-
nificantly more patients with NP symptoms also met the
criteria for FM. Besides experiencing more severe pain,
patients with NP symptoms reported more disability on
the HAQ-DI and worse physical and mental health on the
SF-36. Finally, patients with NP had significantly higher
tender joint scores and total DAS28 scores therefore
tended to be somewhat higher in the NP group.
Multivariable associations with neuropathic pain features
Since current, average and strongest pain were strongly
correlated with pain medication use (r = 0.49–0.53), HAQ-
DI scores (r = 0.64–0.66), and PCS scores (r = 0.67–0.69),
pain severity was not included in the initial multivariable
model. Additionally, the HAQ-DI and PCS (r = −0.75) and
the total DAS28 and TJC28 (r = 0.58) correlated strongly
with each other. As the TJC28 was more strongly associ-
ated with NP in univariate analysis than the total DAS28, it
was selected for inclusion in the multivariable model. Al-
though the HAQ-DI was slightly more strongly associated
with NP than the PCS, the latter was selected over the
HAQ-DI as it provides a more comprehensive assessment
of physical health status than physical disabilities alone.
The initial model without pain severity as a covariate
(Table 4) showed a good fit to the data (Hosmer and
Lemeshow test: χ2(8) = 2.215, P = 0.974). NP symptoms
were independently associated with worse physical and
mental health status. Meeting the FM criteria, self-
reported pain medication, CRP values and number of ten-
der joints were not associated with NP symptoms in multi-
variable analysis. Controlling for current pain severity in
the final model (Hosmer and Lemeshow test: χ2(8) = 4.139,
P = 0.844) did not substantially alter the odds ratios nor
the significance of any of the associations. Additional
models controlling for strongest or average pain severity
instead of current pain severity yielded very similar results.
Discussion
This study assessed the occurrence and associations of
NP-like symptoms in a cohort of patients with relatively
well-controlled RA. Despite almost 75 % of patients be-
ing in DAS28 remission, 44 % still reported clinically sig-
nificant pain. According to the PainDETECT, 17 % of all
patients had likely NP, while 21 % had possible NP features.
These patients were shown to have more severe pain, used
pain medication more often, and reported lower quality of
life. Multivariable logistic analysis showed that the occur-
rence of possible or likely NP-like features was independ-
ently associated with worse physical and mental health,
even when controlling for pain severity.
Despite the relatively low disease activity in the current
cohort, nearly half of the patients still reported clinically
significant pain. Clinically significant pain was defined as
an average pain score ≥4. This threshold was based on sev-
eral previous studies that identified pain intensity levels ≥4
out of 10 as moderate to severe or unacceptable [28, 29].
This confirms that, despite improvements in the manage-
ment of RA, pain control remains inadequate in some pa-
tients, even when inflammation is well controlled [3].
Consequently, although inflammation contributes to pain
in RA, it may not be the only factor and other pain mecha-
nisms such as NP may also play a role.
The findings of this study suggest that the pain of a
substantial number of RA patients may have neuropathic
features or a neuropathic component, as has also been
shown in other rheumatic conditions. NP symptoms
have only been sporadically tested in RA samples. The
17 % proportion of RA patients with likely NP found in
this study was very similar to the 19 % prevalence re-
ported by Meirinhos et al. [21]. Conversely, Ahmed et al.
[20] reported that 28 % of RA patients had possible NP
symptoms and 5 % were likely to be experiencing NP
symptoms according to the painDETECT. The relatively
high proportion of patients (36 %) with NP in the study
by Perrot et al. [22] may have resulted from their use of
the DN4 questionnaire, which tends to have a high sen-
sitivity but low specificity in identifying NP [30].
Table 2 Pain intensity and sensory symptoms (painDETECT)
Etiology, mean ± SD
Current pain (0–10) 3.3 ± 2.4
Strongest pain (0–10) 4.3 ± 2.9
Average pain (0–10) 3.5 ± 2.4
Clinically relevant complaint (score >3), n (%)
Q1, burning 38 (23.9)
Q2, prickling 39 (24.5)
Q3, allodynia 27 (17.0)
Q4, attacks 55 (34.6)
Q5, thermal 21 (13.2)
Q6, numbness 39 (24.5)
Q7, pressure 72 (45.3)
Patterns
Persistent pain with slight fluctuations 70 (44.0)
Persistent pain with pain attacks 15 (9.4)
Pain attacks without pain between them 57 (35.8)
Pain attacks with pain between them 17 (10.7)
Radiating pain (yes), n (%) 58 (36.5)
PainDETECT total score (0–38), mean ± SD 10.5 ± 6.8
Neuropathic pain, n (%) 4.8 ± 1.5
Unlikely (0–12) 98 (61.6)
Possible (13–18) 34 (21.4)
Likely (19–38) 27 (17.0)
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Table 3 Comparison of patients with (painDETECT ≥13) and without neuropathic pain symptoms
No NP NP P
Symptoms Symptoms
Female sex, n (%) 61 (62.2) 43 (70.5) 0.288
Age (years), mean ± SD 57.7 (10.9) 56.3 (11.0) 0.432
Education, n (%)
Low 22 (22.4) 15 (25.0)
Medium 57 (58.2) 36 (60.0)
High 19 (19.4) 9 (15) 0.768
Current smoking, n (%) 15 (15.3) 12 (19.7) 0.476
Current alcohol, n (%) 73 (74.5) 47 (77.0) 0.715
Disease duration (years), median (IQR) 6.0 (3.0–12.0) 6.0 (3.0–12.0) 0.912
FM, n (%) 6 (6.1) 17 (28.3) <0.001
Prescribed RA medication, n (%)
DMARD 58 (59.2) 37 (60.7) 0.854
DMARD plus biologic 25 (25.5) 15 (24.6) 0.897
Biologic 11 (11.2) 7 (11.5) 0.961
NSAID only 3 (3.1) 2 (3.3) 1.000
Self-reported current pain medication, n (%) 37 (37.8) 44 (73.3) <0.001
Self-reported current neuropathic pain medication, n (%) 4 (4.1) 5 (8.3) 0.263
Current pain (0–10), mean ± SD 2.5 (2.2) 4.6 (2.3) <0.001
Strongest pain (0–10), mean ± SD 3.2 (2.6) 6.0 (2.3) <0.001
Average pain (0–10), mean ± SD 2.7 (2.2) 4.8 (2.1) <0.001
DAS28 (0–10), mean ± SD 2.0 (1.0) 2.3 (1.0) 0.095
ESR (mm/hour), median (IQR) 8.0 (2.5–15.0) 8.0 (5.0–17.0) 0.610
CRP (mg/l), median (IQR) 2.0 (1.0–7.0) 3.0 (2.0–8.0) 0.107
SJC (0–28), mean ± SD 0 (0–1) 0 (0–1) 0.603
TJC (0–28), mean ± SD 0 (0–1) 0 (0–2) 0.016
HAQ-DI (0–3), mean ± SD 0.5 (0.5) 1.1 (0.6) <0.001
SF-36 PCS (0–100), mean ± SD 44.9 (8.2) 36.4 (8.7) <0.001
SF-36 MCS (0–100), mean ± SD 52.7 (9.4) 46.5 (10.6) <0.001
CRP C-reactive protein, DAS28 28-joint Disease Activity Score, DMARD disease-modifying antirheumatic drug, ESR erythrocyte sedimentation rate, FM fibromyalgia,
HAQ-DI Health Assessment Questionnaire disability index (standard scoring), IQR interquartile range, MCS mental component summary, NP neuropathic pain, NSAID
nonsteroidal anti-inflammatory drug, PCS physical component summary, RA rheumatoid arthritis, SF-36 36-item Short-Form health survey, SJC swollen joint count,
TJC tender joint count
Table 4 Multivariable associations with neuropathic pain symptoms (painDETECT ≥13)
Initial model Final model
OR (95 % CI) P OR (95 % CI) P
Current pain – – 1.08 (0.86–1.35) 0.525
FM 1.73 (0.53–5.60) 0.360 1.78 (0.54–5.67) 0.350
Self-reported current pain medication 2.24 (0.98–5.15) 0.056 2.06 (0.87–4.92) 0.102
CRP 0.99 (0.94–1.05) 0.816 0.99 (0.94–1.04) 0.795
Number of TJC 0.96 (0.84–1.09) 0.508 0.95 (0.83–1.08) 0.434
SF-36 PCS 0.90 (0.86–0.95) <0.001 0.91 (0.86–0.97) 0.003
SF-36 MCS 0.96 (0.92–0.99) 0.021 0.96 (0.92–1.00) 0.046
Nagelkerke R2 = 0.36 for both models
CI confidence interval, CRP C-reactive protein, FM fibromyalgia, MCS mental component summary, OR odds ratio, PCS physical component summary, SF-36 36-item
Short-Form health survey, TJC tender joint count
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With respect to possible NP symptoms in patients with
RA, it should be noted that although inflammatory pain
and NP are attributed to different mechanisms, they do
have some features in common which may confound the
results of NP screeners. Most notably, the painDETECT
item dealing with pain with slight pressure may also re-
flect typical inflammatory joint pain. Removing this item
from the total painDETECT score lowered the proportion
of patients with possible NP from 38.4 % to 29 % in the
current study.
The proportion of RA patients with likely NP was
clearly lower than that usually reported in patients with
osteoarthritis [9–11] and much lower than that found in
patients with FM [12, 13]. Many recent studies have sug-
gested the NP-like symptoms in rheumatic conditions to
be manifestations of dysregulation of central pain pro-
cessing mechanisms [8, 12, 31–38]. Central sensitization
is the increased responsiveness of nociceptive neurons in
the central nervous system to normal input and the re-
cruitment of a response to normally subthreshold inputs
[39]. The precise mechanisms behind this pain augmen-
tation are not known as yet, but most likely encom-
passes multiple changes in the central nervous system.
In acute pain, sensitization is a physiological process to
induce the body to protect damaged tissue and to give it
time to heal and is thus an important mechanism for
survival. It is hypothesized that in chronic pain condi-
tions this adaptive pain mechanism persists despite elim-
ination of the original nociceptive input and thus
provides a deranged pathological mechanism for persist-
ent pain [40]. The finding that the number of RA pa-
tients concurrently fulfilling the current criteria for FM,
often considered the prototypical central pain syndrome
[41], was substantially higher among those with NP fea-
tures provides support to this theory for RA patients as
well.
No previous studies have thoroughly examined multivar-
iable associations of NP symptoms with sociodemographic,
clinical, and quality of life-related factors in patients with
RA. In the current study, NP symptoms were not related
to any of the sociodemographic characteristics included.
Moreover, while the TJC was significantly higher in the NP
group, the more objective parameters of disease activity,
such as CRP, ESR and the SJC, did not differ between the
two groups. The TJC and the global health score are largely
subjective measures and thus may not necessarily reflect
clinical disease activity. Previous studies have shown that
some patients fail to reach RA remission criteria due to
poor patient-reported health scores only [42, 43]. When
comparing DAS28 scores in RA and FM patients, FM pa-
tients tend to score higher on subjective parameters, while
RA patients score worse on objective measures [44]. Simi-
larly, Ranzolin et al. [45] found that RA patients with co-
existent FM had significantly higher DAS28 scores mostly
caused by the TJC and general health scores. As such, this
also points to other mechanisms than inflammation as a
cause for pain in certain RA patients.
Finally, the finding that NP symptoms were independ-
ently associated with physical and mental health status is
in accordance with studies in patients with established
peripheral or central neuropathology, such as diabetic
neuropathy and spinal cord injury. These studies have
consistently shown that the presence and severity of NP
is associated with substantial impairments in most im-
portant health-related quality of life domains [46, 47].
Studies in osteoarthritis also showed that the occurrence
of NP-like symptoms was strongly correlated with a
worse quality of life, more distress, and higher pain in-
tensity [10, 17].
Taken together, the findings of the current study pro-
vide preliminary support of a noninflammatory pain
component in RA. This could have important implica-
tions for RA treatment strategies. The current goal in
the treatment of RA is to reach early sustained remis-
sion. This is increasingly done by intensive treat-to-
target strategies, aimed at DAS28 remission criteria.
When remission is not reached, drug therapy is adjusted.
This can range from a dose change, starting combination
therapy with a second DMARD or glucocorticoids, or
the start of biologicals. These latter are expensive ther-
apies and have, as do all medications, unwanted and in
some cases serious side effects. Furthermore, all these
strategies specifically target inflammation. If, however,
mechanisms other than inflammation, for example hyper-
sensitivity, contribute to a high DAS28 and therefore not
reaching remission, these expensive medications will not
likely have the desired effect. Overtreatment could there-
fore be an outcome in some RA patients. In these cases,
pain treatment targeting the NP-like symptoms might be
more appropriate than intensifying anti-inflammatory
treatment. This treatment could comprise neuromodula-
tors and certain antidepressants. Both these drug groups
appear to be effective in NP [48]. In FM, a syndrome hy-
pothesized to be caused by central pain processing abnor-
malities, these drugs have also been shown to have an
effect, albeit small, on pain [49, 50]. If effective in RA pa-
tients with NP-like symptoms who fail to reach remission,
these therapies could be more cost-effective and, more im-
portantly, result in a better quality of life than current
treatment strategies.
Our study has several strengths. First, it combines the
painDETECT questionnaire with clinical data, the DAS28
score and measurements of FM, quality of life, and disabil-
ity. This gives insight into the origin of pain in RA pa-
tients, but also the effect it has on the daily life of patients.
Second, the patients included in this study were recruited
from normal daily clinical practice and therefore closely
resemble the current ‘well-controlled’ RA patient. The
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findings, however, may not be applicable to RA popula-
tions with less well-controlled disease. Furthermore, since
our population consisted of predominately white patients,
the findings may not be generalizable to more ethnically
diverse populations.
The major limitation of the study is the absence of a gold
standard for NP or central sensitization. This is a problem
inherent to the field. Central sensitization especially is a
relatively new concept, and objective measurements do not
yet exist. The gold standard is thus usually based on a
combination of quantitative sensory testing and clinical or
expert opinion. Additionally, the cross-sectional nature of
this study does not allow any determination of the direc-
tion of associations between NP symptoms and clinical
variables. Finally, the painDETECT was developed as a
screening tool for NP, not central sensitization. Although
symptoms of NP and central sensitization may be similar,
they are by no means the same. The occurrence of NP
symptoms according to the painDETECT therefore does
not measure central sensitization per se, but may be useful
in assisting in the identification of central sensitization [12].
More research, however, is needed to develop validated
tools for the specific identification of central sensitization.
Conclusions
This study demonstrates that neuropathic-like pain symp-
toms are present in a substantial number of patients with
RA and are associated with worse physical and mental
health. These symptoms may represent central sensitization
and underscore the need for further research and screening
of pain mechanisms in RA patients.
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severity score; TJC: Tender joint count; WPI: Widespread pain index.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors participated in the preparation of the manuscript in a significant way.
SMWK, PMtK and HEV conceived the study and design. SMWK drafted the first
version of the manuscript. PMtK, HEV, LMMS and MAFJvdL revised it critically for
important intellectual content. SMWK, PMtK and LMMS performed the statistical
analysis. All authors participated in the interpretation of the results and approved
the final version of the manuscript.
Author details
1Department of Internal Medicine, Hospital Group Twente, Almelo, The
Netherlands. 2Arthritis Center Twente, Department of Psychology, Health and
Technology, University of Twente, Enschede, The Netherlands. 3Arthritis
Center Twente, Department of Rheumatology and Clinical Immunology,
Medical Spectrum Twente, Enschede, The Netherlands.
Received: 11 June 2015 Accepted: 20 August 2015
References
1. Ten Klooster PM, Veehof MM, Taal E, van Riel PL, van de Laar MA. Changes in
priorities for improvement in patients with rheumatoid arthritis during 1 year
of anti-tumour necrosis factor treatment. Ann Rheum Dis. 2007;66:1485–90.
2. Lee YC. Effect and treatment of chronic pain in inflammatory arthritis. Curr
Rheumatol Rep. 2013;15:300.
3. Lee YC, Cui J, Lu B, Frits ML, Iannaccone CK, Shadick NA, et al. Pain persists in
DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a
longitudinal observational study. Arthritis Res Ther. 2011;13:R83.
4. Burckhardt CS. The use of the McGill Pain Questionnaire in assessing arthritis
pain. Pain. 1984;19:305–14.
5. Charter RA, Nehemkis AM, Keenan MA, Person D, Prete PE. The nature of
arthritis pain. Br J Rheumatol. 1985;24:53–60.
6. Roche PA, Klestov AC, Heim HM. Description of stable pain in rheumatoid
arthritis: a 6 year study. J Rheumatol. 2003;30:1733–8.
7. Treede R-D, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et
al. Neuropathic pain: redefinition and a grading system for clinical and
research purposes. Neurology. 2008;70:1630–5.
8. Woolf CJ. What is this thing called pain? J Clin Invest. 2010;120:3742–4.
9. Hochman JR, French MR, Bermingham SL, Hawker GA. The nerve of osteoarthritis
pain. Arthritis Care Res (Hoboken). 2010;62:1019–23.
10. Hochman JR, Gagliese L, Davis AM, Hawker GA. Neuropathic pain symptoms
in a community knee OA cohort. Osteoarthr Cartil. 2011;19:647–54.
11. Oteo-Álvaro A, Ruiz-Ibán MA, Miguens X, Stern A, Villoria J, Sánchez-Magro I.
High prevalence of neuropathic pain features in patients with knee
osteoarthritis: a cross-sectional study. Pain Pract. 2014. doi:10.1111/papr.12220.
12. Amris K, Jespersen A, Bliddal H. Self-reported somatosensory symptoms of
neuropathic pain in fibromyalgia and chronic widespread pain correlate
with tender point count and pressure-pain thresholds. Pain. 2010;151:664–9.
13. Rehm S, Koroschetz J, Gockel U. A cross-sectional survey of 3035 patients with
fibromyalgia: subgroups of patients with typical comorbidities and sensory
symptom profiles. Rheumatol. 2010;49:1146–52.
14. Wu Q, Inman RD, Davis KD. Neuropathic pain in ankylosing spondylitis: a
psychophysics and brain imaging study. Arthritis Rheum. 2013;65:1494–503.
15. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms,
and management. Lancet. 1999;353:1959–64.
16. Soni A, Batra RN, Arden EJ, Hart D, Spector TD, Arden NK, et al. Prevalence
and predictors of knee pain with neuropathic features in a community
based cohort. Osteoarthr Cartil. 2012;20:S255–6.
17. Valdes AM, Suokas AK, Doherty SA, Jenkins W, Doherty M. History of knee
surgery is associated with higher prevalence of neuropathic pain-like
symptoms in patients with severe osteoarthritis of the knee. Semin Arthritis
Rheum. 2014;43:588–92.
18. Bennett MI, Attal N, Backonja MM, Baron R, Bouhassira D, Freynhagen R, et al.
Using screening tools to identify neuropathic pain. Pain. 2007;127:199–203.
19. Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening
questionnaire to identify neuropathic components in patients with back
pain. Curr Med Res Opin. 2006;22:1911–20.
20. Ahmed S, Magan T, Vargas M, Harrison A, Sofat N. Use of the painDETECT
tool in rheumatoid arthritis suggests neuropathic and sensitization
components in pain reporting. J Pain Res. 2014;7:579–88.
21. Meirinhos T, Aguiar R, Ambrósio C, Barcelos A. Neuropathic pain in
rheumatic diseases: a cross-sectional study. Ann Rheum Dis. 2014;73:A76.
22. Perrot S, Dieudé P, Pérocheau D, Allanore Y. Comparison of pain, pain
burden, coping strategies, and attitudes between patients with systemic
sclerosis and patients with rheumatoid arthritis: a cross-sectional study. Pain
Med. 2013;14:1776–85.
23. Timmerman H, Wolff AP, Schreyer T, Outermans J, Evers AWM, Freynhagen R,
et al. Cross-cultural adaptation to the Dutch language of the painDETECT
questionnaire. Pain Pr. 2013;13:206–14.
24. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RS, et al.
Fibromyalgia criteria and severity scales for clinical and epidemiological
studies: a modification of the ACR Preliminary Diagnostic Criteria for
Fibromyalgia. J Rheumatol. 2011;38:1113–22.
25. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the
Health Assessment Questionnaire, disability and pain scales. J Rheumatol.
1982;9:789–93.
26. Ware Jr JE. SF-36 health survey update. Spine (Phila Pa 1976). 2000;25:3130–9.
Koop et al. Arthritis Research & Therapy  (2015) 17:237 Page 7 of 8
27. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response
criteria. Clin Exp Rheumatol. 2005;23:S93–9.
28. Gerbershagen HJ, Rothaug J, Kalkman CJ, Meissner W. Determination of
moderate-to-severe postoperative pain on the numeric rating scale: a cut-off
point analysis applying four different methods. Br J Anaesth. 2011;107:619–26.
29. Tubach F, Ravaud P, Martin-Mola E, Awada H, Bellamy N, Bombardier C, et al.
Minimum clinically important improvement and patient acceptable symptom
state in pain and function in rheumatoid arthritis, ankylosing spondylitis,
chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: results
from a prospective multinational study. Arthritis Care Res. 2012;64:1699–707.
30. Hallström H, Norrbrink C. Screening tools for neuropathic pain: can they be
of use in individuals with spinal cord injury? Pain. 2011;152:772–9.
31. Arendt-Nielsen L, Graven-Nielsen T. Central sensitization in fibromyalgia and
other musculoskeletal disorders. Curr Pain Headache Rep. 2003;7:355–61.
32. Abrahams MJ. Neuropathic pain in soft tissue complaints. Best Pract Res Clin
Rheumatol. 2007;21:223–44.
33. Bliddal H, Danneskiold-Samsøe B. Chronic widespread pain in the spectrum of
rheumatological diseases. Best Pract Res Clin Rheumatol. 2007;21:391–402.
34. Hochman JR, Davis AM, Elkayam J, Gagliese L, Hawker GA. Neuropathic pain
symptoms on the modified painDETECT correlate with signs of central
sensitization in knee osteoarthritis. Osteoarthritis Cartilage. 2013;21:1236–42.
35. Soni A, Batra RN, Gwilym SE, Spector TD, Hart DJ, Arden NK, et al. Neuropathic
features of joint pain: a community-based study. Arthritis Rheum.
2013;65:1942–9.
36. Walsh DA, McWilliams DF. Mechanisms, impact and management of pain in
rheumatoid arthritis. Nat Rev Rheumatol. 2014;67:519–28.
37. Moreton BJ, Tew V, das Nair R, Wheeler M, Walsh DA, Lincoln NB. Pain
phenotype in people with knee osteoarthritis; classification and
measurement properties of painDETECT and S-LANSS in a cross-sectional
study. Arthritis Care Res (Hoboken). 2014;67:519–28.
38. Gwilym SE, Keltner JR, Warnaby CE, Carr AJ, Chizh B, Chessell I, et al.
Psychophysical and functional imaging evidence supporting the presence
of central sensitization in a cohort of osteoarthritis patients. Arthritis Rheum.
2009;61:1226–34.
39. Loeser JD, Treede R-D. The Kyoto protocol of IASP Basic Pain Terminology.
Pain. 2008;137:473–7.
40. Staud R. Evidence for shared pain mechanisms in osteoarthritis, low back
pain, and fibromyalgia. Curr Rheumatol Rep. 2011;13:513–20.
41. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311:1547–55.
42. Vermeer M, Kuper HH, van der Bijl AE, Baan H, Posthumus MD, Brus HL, et al.
The provisional ACR/EULAR definition of remission in RA: a comment on the
patient global assessment criterion. Rheumatol. 2012;51:1076–80.
43. Masri KR, Shaver TS, Shahouri SH, Wang S, Anderson JD, Busch RE, et al.
Validity and reliability problems with patient global as a component of the
ACR/EULAR remission criteria as used in clinical practice. J Rheumatol.
2012;39:1139–45.
44. Leeb BF, Andel I, Sautner J, Nothnagl T, Rintelen B. The DAS28 in rheumatoid
arthritis and fibromyalgia patients. Rheumatology (Oxford). 2004;43:1504–7.
45. Ranzolin A, Brenol JCT, Bredemeier M, Guarienti J, Rizzatti M, Feldman D, et al.
Association of concomitant fibromyalgia with worse disease activity score in 28
joints, health assessment questionnaire, and short form 36 scores in patients
with rheumatoid arthritis. Arthritis Rheum. 2009;61:794–800.
46. Haythornthwaite JA, Benrud-Larson LM. Psychological aspects of
neuropathic pain. Clin J Pain. 2000;16:S101–5.
47. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on
health-related quality of life: review and implications. Neurology.
2007;68:1178–82.
48. Argoff CE. The coexistence of neuropathic pain, sleep, and psychiatric disorders:
a novel treatment approach. Clin J Pain. 2007;23:15–22.
49. Uçeyler N, Häuser W, Sommer C. A systematic review on the effectiveness
of treatment with antidepressants in fibromyalgia syndrome. Arthritis
Rheum. 2008;59:1279–98.
50. Moore RA, Wiffen PJ, Derry S, Toelle T, Rice ASC. Gabapentin for chronic
neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev.
2014;4:CD007938.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Koop et al. Arthritis Research & Therapy  (2015) 17:237 Page 8 of 8
